Technology Bundle ID
TAB-3551

Discovery of DPTIP a Small Molecule Inhibitor of Neutral Sphingomyelinase 2 (nSMase2) for the Treatment of Neurodegenerative and Oncologic Diseases

Applications
Linked ID
E-117-2018-0
Lead Inventors
Marc Ferrer-Alegre (NCATS)
Co-Inventors
Ajit Thomas (Johns Hopkins University)
Barbara Slusher (Johns Hopkins University)
Camilo Rojas (Johns Hopkins University)
Norman Haughey (Johns Hopkins University)
Xin Hu (NCATS)
ICs
This technology includes a newly discovered molecule 2,6-Dimethoxy-4-(5-Phenyl-4-Thiophen-2-yl-1H-Imidazol-2-yl)-Phenol (DPTIP) as potent inhibitor of neutral sphingomyelinase 2 (nSMase2), to be used for the treatment of neurodegenerative and oncologic diseases. This discovery was identified through unbiased screening of the National Center for Advancing Chemical Sciences (NCATS) chemical library using our human neutral sphingomyelinase assay. DPTIP is a non-competitive inhibitor with respect to sphingomyelin, it inhibits exosome release both in vitro and in vivo, it is metabolically stable and it penetrates the brain (AUCbrain/AUCplasma = 0.26). Based upon genetic and pharmacological inhibition studies, DPTIP will have broad therapeutic utility in neurodegenerative and oncologic diseases wherein abnormal exosome secretion is presumed pathogenic.
Commercial Applications
Treatment of neurodegenerative diseases and cancer.
Competitive Advantages
Treatment of neurodegenerative diseases and cancer.

Request More Info

Licensing Contact: